The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genome-wide aneuploidy detected in circulating cell-free DNA of patients with metastatic urothelial cancer as a predictive biomarker of response to pembrolizumab.
 
Youssra Salhi
No Relationships to Disclose
 
Maud Rijnders
No Relationships to Disclose
 
Pauline Mendelaar
No Relationships to Disclose
 
Vania de Weert
No Relationships to Disclose
 
Corine Beaufort
No Relationships to Disclose
 
R Head
No Relationships to Disclose
 
Hans M. Westgeest
No Relationships to Disclose
 
Jens Voortman
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); eTheRNA Immunotherapies (Inst); lava therapeutics (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Ipsen; Merck; Pfizer; Pfizer; Pfizer; Sanofi; TEVA
 
Maureen J.B. Aarts
No Relationships to Disclose
 
John W.M. Martens
Research Funding - Cytotrack; GlaxoSmithKline; Pfizer
 
Astrid Aplonia Maria Van Der Veldt
No Relationships to Disclose
 
Ronald De Wit
Consulting or Advisory Role - Astellas Pharma; Bayer; Hengrui Medicine; Orion
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer
 
Saskia M Wilting
Research Funding - Pfizer (Inst)
 
Debbie Robbrecht
Consulting or Advisory Role - Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Merck KGaA (Inst)